N
Nektar Therapeutics (NKTR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$36.44
-0.83 (-2.23%)
Market Cap: $1.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nektar Therapeutics (NKTR) Valuation Multiples
Nektar Therapeutics (NKTR) trades at 23.9x sales and 1.5x book value. Its P/S of 23.9x is above its 5-year median of 4.7x. Its forward P/E is 34.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 34.0x |
| Price to sales | 23.9x |
| Price to book | 1.5x |
| PEG | N/A |
| FCF yield | -20.7% |
Historical Medians
Against its 10-year medians, its P/S is 54.2% above 15.5x and its P/B is 54.5% below 3.3x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 23.9x | 4.7x | 15.5x |
| P/B | 1.5x | 2.4x | 3.3x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.2x in 2023 to 40.8x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $42.28 | N/A | 13.1x | 9.6x |
| 2024 | $13.94 | N/A | 2.0x | 3.3x |
| 2023 | $8.47 | N/A | 1.2x | 0.8x |
| 2022 | $33.88 | N/A | 4.6x | 1.2x |
| 2021 | $202.55 | N/A | 24.3x | 3.7x |
| 2020 | $254.87 | N/A | 28.8x | 2.8x |
| 2019 | $323.69 | N/A | 33.0x | 2.7x |
| 2018 | $492.80 | 8.0x | 4.7x | 3.3x |
| 2017 | $895.35 | N/A | 40.8x | 111.0x |
| 2016 | $183.96 | N/A | 10.3x | 20.7x |
Frequently Asked Questions About NKTR
What is NKTR's forward P/E ratio?
Nektar Therapeutics has a forward P/E ratio of 34.0x.
What is NKTR's price to sales ratio?
Nektar Therapeutics has a price to sales ratio of 23.9x.
NKTR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors